SCHEMBL19486469

SCHEMBL19486469

O=CN1CCN(c2ccnn3cc(-c4ccc(N5CCNCC5)cc4)cc23)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP4 P12644 2/20 0.46
ACVR1 Q04771 7/20 0.43
KHK P50053 3/20 0.43
KDR P35968 3/20 0.43
TGFBR1 P36897 3/20 0.43
PRKAB1 Q9Y478 3/20 0.43
BMPR1B O00238 5/20 0.41
ACVRL1 P37023 5/20 0.41
BMPR1A P36894 4/20 0.41
ACVR1B P36896 4/20 0.41
TGFBR2 P37173 2/20 0.41
BMPR2 Q13873 2/20 0.41
RIPK2 O43353 1/20 0.41
ACVR2A P27037 1/20 0.41
ACVR2B Q13705 1/20 0.41
RET P07949 1/20 0.40
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19486329 0.85 CHRNA7 (0.44) KHKMAP4K4KIT
SCHEMBL19486352 0.85 KIT (0.39) ACVR1KHKTGFBR1MAP4K4KIT
SCHEMBL19486444 0.85 KIT (0.42) RETMAP4K4KIT
SCHEMBL21679774 0.82 KHK (0.43) BMP4ACVR1KHKKDRTGFBR1
SCHEMBL19458948 0.81 TDP1 (0.45) BMP4ACVR1KHKKDRTGFBR1
SCHEMBL19462890 0.79 RET (0.45) BMP4ACVR1KHKKDRTGFBR1
SCHEMBL19481700 0.79 MAPT (0.47) ACVR1KHKRET
SCHEMBL19481702 0.79 MAPT (0.44) BMP4ACVR1KHKKDRTGFBR1
SCHEMBL19486447 0.79
SCHEMBL19486470 0.79 KIT (0.36) RETMAP4K4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 BMP4 22/4885ACVR1 1/4885KHK 2328/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 BMP4 21/4885ACVR1 1/4885KHK 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.